FEN

First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex

Anastrozole (ArimidexTM) improves overall survival inpostmenopausal women with early breast cancer receiving treatmentwith tamoxifen – Survival benefit demonstrated for an AI over tamoxifenin a single trial – LUTON, England, Friday 15 June 2007: Analysis of the entirepopulation of a single trial has demonstrated that survival inearly breast cancer can be signific...

Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen

Survival Benefit Demonstrated for an AI Over Tamoxifen ina Single Trial LUTON, UK, Friday 15 June 2007: Analysis of the entirepopulation of a single trial has demonstrated that survival inearly breast cancer can be significantly improved by switching fromtamoxifen to anastrozole (Arimidex). An analysis of the'Arimidex'-'Nolvadex 95' (ARNO 95) study, published online in TheJourna...

Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension

* New data from 741-patient trial show those treated withPrexige experienced significantly smaller impact on blood pressurecompared to ibuprofen[1] * Many patients with osteoarthritis also have high bloodpressure; even small changes in blood pressure can impactcardiovascular risk[2],[3] * Prexige approved in more than 50 countries and currently underreview in US for use in o...

Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension

New data From 741-patient Trial Show Those Treated with LumiracoxibExperienced Significantly Smaller Impact on Blood Pressure Comparedto Ibuprofen EAST HANOVER, N.J., June 15, 2007 /PRNewswire/ -- Patients withosteoarthritis who also have controlled hypertension experienced aslight decrease in average daily blood pressure when treated withthe investigational selective COX-2 inhibitor lumi...

Trial Results with Intranasal Fentanyl Hold Promise for Treatment of Breakthrough Pain in Cancer

<p style="MARGIN: 0in 0in 0pt; LINE-HEIGHT: 150%; mso-hyphenate: none">BUDAPEST, Hungary, June, 7, 2007--A pioneering nasal spraycould stop thousands of patients with cancer from sufferingunnecessary pain; it was reported today1 at the 10th Congress ofthe European Association for Palliative Care, Budapest, 7–9June. The study investigated whether this first in class novelformulation c...

Archimedes Pharma Presents Positive Efficacy and Safety Data on Nasalfent at European Association for Palliative Care Congress

Nasalfent shows clinically meaningful pain relief within 5minutes of dosing and is well-tolerated READING, England, 7 June 2007 - Archimedes Pharma Ltd("Archimedes"), a European specialty pharmaceutical company, todaypresented new clinical data from a Phase II study of Nasalfent(r),an innovative fentanyl citrate nasal spray aimed at providing afast, effective and convenient treatme...

BDSI Announces Positive Key Secondary Efficacy Endpoint Results for Bema Fentanyl

MORRISVILLE, N.C.--(BUSINESS WIRE)--May 14, 2007 - BioDeliverySciences International, Inc. (Nasdaq: BDSI) announced additionalstatistically significant results with BEMA Fentanyl in cancerpatients with breakthrough pain in its Phase III efficacy clinicaltrial for the product. Results were based on the company's continuing analysis of thesecondary efficacy endpoints from the study. A key s...

Bema Fentanyl Demonstrates Substantial Transmucosal Delivery In Absolute Bioavailability Study

MORRISVILLE, N.C.--(BUSINESS WIRE)--May 7, 2007 - BioDeliverySciences International, Inc. (Nasdaq:BDSI) announced the results ofa 12 subject, crossover study comparing the absorption of fentanylfrom both single and multiple BEMA(TM) Fentanyl discs, as well asoral and intravenous doses of fentanyl. The data demonstrates thatthe absolute bioavailability (i.e. the total amount absorbed fromthe...

Cephalon Presents Positive Results for Fentora in Breakthrough Pain Associated with Neuropathic Conditions

All Efficacy Measures Reached Statistical Significance FRAZER, Pa., May 01, 2007 /PRNewswire-FirstCall/ -- A Cephalon,Inc. Phase 3 clinical trial presented today at the 59th AnnualMeeting of the American Academy of Neurology in Boston highlightsdata demonstrating that FENTORA(R) (fentanyl buccal tablet) [C-II]is beneficial for the treatment of breakthrough pain in patientswith...

BDSI Announces Positive Phase III Clinical Trial Results for BEMA Fentanyl

MORRISVILLE, N.C.--(BUSINESS WIRE)--Apr 25, 2007 - BioDeliverySciences International, Inc. (Nasdaq: BDSI) announced todaystatistically significant results with BEMA(TM) Fentanyl in cancerpatients with breakthrough pain in its pivotal Phase III efficacyclinical trial for the product. The results are based onachievement of the primary efficacy endpoint of the trial, Summaryof Pain Intensity D...

Inimex Product Candidate is First Immune Defense Regulator to Cure Infections Without Causing Harmful Inflammation

Novel Approach to Address Growing Problem of Antibiotic ResistancePublished in Nature Biotechnology VANCOUVER, British Columbia, March 26, 2007 /PRNewswire/ --Inimex Pharmaceuticals Inc.'s product candidate IDR-1 is the firstimmune system trigger to cure infections without causing harmfulinflammation, according to a paper published in the April 2007issue of Nature Biotechnology. Th...